A reliable and stable method for determination of brigatinib in rat plasma by UPLC–MS/MS: Application to a pharmacokinetic study

Wen, Jian Ming; Bao, Su-su; Cai, Yingying; Zhang, Bowen; Wang, Rongrong; Wang, Chenchen; Hu, Guoxin

doi:10.1016/j.jchromb.2017.10.007

Cited by 10 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein precipitation method by acetonitrile has been selected for the protein precipitation to assay other TKIs in the reported studies [20–22]. In this study, we used the protein precipitation method with acetonitrile in sample preparation for its simple isolation procedure.…”

Section: Discussionmentioning

confidence: 99%

Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study

Wang

Lian

Dong

et al. 2019

Journal of Analytical Methods in Chemistry

View full text Add to dashboard Cite

Anlotinib is a novel inhibitor of receptor kinase tyrosine with multitargets and has a broad spectrum of inhibitory action on tumor angiogenesis and growth. A simple and rapid UHPLC-MS/MS bioanalytical method was validated for the determination of anlotinib in rat plasma, using imatinib as an internal standard. An Acquity BEH C18 column was used to separate analytes. The eluents consisted of formic acid/water (0.1 : 100, v/v) and acetonitrile with a mobile phase. A triple quadrupole mass spectrometer was operated for the quantification with multiple reaction monitoring (MRM) to determine transitions: 408.2 ⟶ 339.1 for anlotinib, and 494.3 ⟶ 394.1 for imatinib. The validated range was 0.1–50 ng/mL for anlotinib. Mean recovery rate of anlotinib in plasma was ≥99.32% and reproducible. Also, the intra- and interday precisions were both below 15%. This robust method was successfully applied to support the pharmacokinetic study of anlotinib in rats.

show abstract

Section: Discussionmentioning

confidence: 99%

Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study

Wang

Lian

Dong

et al. 2019

Journal of Analytical Methods in Chemistry

View full text Add to dashboard Cite

show abstract

“…Positive mode was used for BGB detection as BGB chemical structure contains many basic nitrogen that can be easily protonated and this matched with the literature. 33 Product ions (PIs) of BGB, in vitro phase I metabolites and cyano adducts in the collision cell. LC-MS/MS system and data acquisition were controlled by Mass Hunter software.…”

Section: Chemicals and Methodsmentioning

confidence: 99%

“…PI mode gave more qualitative information comparing to multiple reaction monitoring mode which is mainly used for quantification as stated in the LC-MS/MS method for quantification of BGB. 33 Extracted ion chromatogram (EIC) of m / z of the supposed BGB related metabolites was used to locate and characterize in vitro phase I and reactive metabolites in the total ion chromatogram of the metabolic mixture extract. Comparison of the EICs of the metabolic extract was done with control incubations (that does not contain either BGB or RLMs).…”

Section: Chemicals and Methodsmentioning

confidence: 99%

LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways

2018

View full text Add to dashboard Cite

show abstract

“…DNA methylation can cause changes in chromatin structure, DNA conformation, DNA stability and the way DNA interact with proteins, thus controlling gene expression [8] . DNA methylation reaction can be divided into two types, which are ab initio methylation and retention methylation [9] . As a stable modification state, DNA methylation can be inherited to newborn offspring DNA along with the process of DNA replication, which is an important epigenetic mechanism [10] .…”

Section: Luo Et Al: Dna Abnormal Methylation In the Development Of Lung Cancer In Ratsmentioning

confidence: 99%

Mechanisms of DNA Abnormal Methylation in the Development of Lung Cancer in Rats

Luo¹,

Hu²,

Tang³

2021

ijps

View full text Add to dashboard Cite

In order to study the mechanism of abnormal deoxyribonucleic acid methylation in the process of lung cancer in rats, Wistar rats are used as the research object. The lung cancer model of rats is established by bronchial perfusion of carcinogens. Hematoxylin-eosin staining is used to observe the pathological changes of lung tissue in rats. The overall methylation level of genome is analyzed by immunohistochemistry, and the methylation status is detected by methylation specific polymerase chain reaction. The results show that the nuclei of normal bronchial epithelial cells are brown and yellow uder optical microscope. With the development of carcinogenesis, the staining gradually fades to light yellow in the infiltrating nuclei of cancer cells. Compared with normal bronchial epithelial cells, the optical density and integrated optical density values of 5-mC immunohistochemistry decrease. The methylation frequency of p16 gene in atypical hyperplasia, carcinoma in situ and invasive cancer tissues is significantly higher than that in normal and proliferative tissues. The methylation frequency of p57 gene is significantly higher in carcinoma in situ and invasive tissues than in normal and proliferative tissues. Abnormal methylation-mediated down-regulation of p16 and p57 gene transcription may be an important molecular biological event in carcinogenesis of lung cancer rats induced by carcinogens. There are still some shortcomings in the research process, but the results of the study still provide some reference and guidance for exploring more precise mechanism in the future. Therefore, this study is a significant research topic.

show abstract

A reliable and stable method for determination of brigatinib in rat plasma by UPLC–MS/MS: Application to a pharmacokinetic study

Cited by 10 publications

References 23 publications

Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study

Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study

LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways

Mechanisms of DNA Abnormal Methylation in the Development of Lung Cancer in Rats

Contact Info

Product

Resources

About